Sangstat Medical Corp., a privately held Menlo Park, Calif.,company focusing on therapeutic monitoring products for organand cell transplantation, said Tuesday it has completed a $4million third round of venture capital financing.

The lead investors are the U.S. and European funds of PartechInternational, an affiliate of Paribas, a French bank. Otherinvestors include Athena Ventures, Euro-America, IAI VenturePartners, Sequoia Capital, Siparex and Branco Weiss.

(c) 1997 American Health Consultants. All rights reserved.